Targets › UBA3
5 programs from 5 companies in 6 trials: 3 Phase 1, 2 Phase 2, 1 Phase 3; Oncology; next expected readout Nov 2026.
Catalytic subunit of the dimeric UBA3-NAE1 E1 enzyme. E1 activates NEDD8 by first adenylating its C-terminal glycine residue with ATP, thereafter linking this residue to the side chain of the catalytic cysteine, yielding a NEDD8-UBA3 thioester and free AMP. E1 finally transfers NEDD8 to the catalytic cysteine of UBE2M. Down-regulates steroid receptor activity. (UniProt, Q8TBC4)
Open in Phaseline: the race on UBA3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| PETHEMA Foundation | Pevonedistat NEDD8 activating enzyme inhibitor | UBA3, NAE1 | Phase 3 | Leukemia, Myeloid, Acute | – |
| National Cancer Institute (NCI) | Pevonedistat NEDD8 activating enzyme inhibitor | UBA3, NAE1 | Phase 2 | Metastatic Lung Non-Small Cell Squamous Carcinoma; Metastatic Cholangiocarcinoma | Mar 2027 |
| City of Hope Medical Center | Pevonedistat NEDD8 activating enzyme inhibitor | UBA3, NAE1 | Phase 1 | B-Cell Prolymphocytic Leukemia | Nov 2026 |
| University of Southern California | Pevonedistat NEDD8 activating enzyme inhibitor | UBA3, NAE1 | Phase 1 | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Dec 2026 |
| M.D. Anderson Cancer Center | Pevonedistat NEDD8 activating enzyme inhibitor | UBA3, NAE1 | Phase 1 | Acute Myeloid Leukemia | Jan 2027 |
B-Cell Prolymphocytic Leukemia (1) Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (1) Metastatic Lung Non-Small Cell Squamous Carcinoma (1) Metastatic Cholangiocarcinoma (1) Acute Myeloid Leukemia (1) Leukemia, Myeloid, Acute (1)
small molecule (4), mixed (1)
City of Hope Medical Center (1) University of Southern California (1) National Cancer Institute (NCI) (1) M.D. Anderson Cancer Center (1) PETHEMA Foundation (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.